D. Blake, A. Weir, . Newey, . Se, and K. Davies, Function and Genetics of Dystrophin and Dystrophin-Related Proteins in Muscle, Physiological Reviews, vol.82, issue.2, pp.291-329, 2002.
DOI : 10.1152/physrev.00028.2001

J. Ervasti, Dystrophin, its interactions with other proteins, and implications for muscular dystrophy, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol.1772, issue.2, pp.108-117, 2007.
DOI : 10.1016/j.bbadis.2006.05.010
URL : https://hal.archives-ouvertes.fr/hal-00562718

D. Chao, J. Gorospe, J. Brenman, J. Rafael, . Peters et al., Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy, Journal of Experimental Medicine, vol.184, issue.2, pp.609-618, 1996.
DOI : 10.1084/jem.184.2.609

K. Wells, S. Torelli, Q. Lu, . Brown, . Sc et al., Relocalization of neuronal nitric oxide synthase (nNOS) as a marker for complete restoration of the dystrophin associated protein complex in skeletal muscle, Neuromuscular Disorders, vol.13, issue.1, pp.21-31, 2003.
DOI : 10.1016/S0960-8966(02)00191-8

Y. Lai, . Thomas, . Gd, Y. Yue, . Yang et al., Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy, Journal of Clinical Investigation, vol.119, issue.3, pp.624-635, 2009.
DOI : 10.1172/JCI36612DS1

S. Kameya, Y. Miyagoe, I. Nonaka, T. Ikemoto, M. Endo et al., ??1-Syntrophin Gene Disruption Results in the Absence of Neuronal-type Nitric-oxide Synthase at the Sarcolemma but Does Not Induce Muscle Degeneration, Journal of Biological Chemistry, vol.274, issue.4, pp.2193-2200, 1999.
DOI : 10.1074/jbc.274.4.2193

M. Adams, . Mueller, . Ha, . Froehner, and . Sc, In vivo requirement of the ??-syntrophin PDZ domain for the sarcolemmal localization of nNOS and aquaporin-4, The Journal of Cell Biology, vol.76, issue.1, pp.113-122, 2001.
DOI : 10.1083/jcb.200106158

J. Brenman, . Chao, . Ds, H. Xia, . Aldape et al., Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy, Cell, vol.82, issue.5, pp.743-752, 1995.
DOI : 10.1016/0092-8674(95)90471-9

Y. Kobayashi, . Rader, . Ep, R. Crawford, . Iyengar et al., Sarcolemma-localized nNOS is required to maintain activity after mild exercise, Nature, vol.34, issue.7221, pp.511-515, 2008.
DOI : 10.1038/nature07414

M. Wehling, . Spencer, and J. Tidball, A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice, The Journal of Cell Biology, vol.94, issue.1, pp.123-131, 2001.
DOI : 10.1038/384349a0

S. Brunelli, C. Sciorati, D. Antona, G. Innocenzi, A. Covarello et al., Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy, Proceedings of the National Academy of Sciences, vol.104, issue.1, pp.264-269, 2007.
DOI : 10.1073/pnas.0608277104

C. Colussi, C. Mozzetta, A. Gurtner, B. Illi, J. Rosati et al., HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment, Proceedings of the National Academy of Sciences, vol.105, issue.49, pp.19183-19187, 2008.
DOI : 10.1073/pnas.0805514105

G. Minetti, C. Colussi, R. Adami, C. Serra, C. Mozzetta et al., Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors, Nature Medicine, vol.96, issue.10, pp.1147-1150, 2006.
DOI : 10.1038/nm1479

D. Cacchiarelli, J. Martone, E. Girardi, M. Cesana, T. Incitti et al., MicroRNAs Involved in Molecular Circuitries Relevant for the Duchenne Muscular Dystrophy Pathogenesis Are Controlled by the Dystrophin/nNOS Pathway, Cell Metabolism, vol.12, issue.4, pp.341-351, 2010.
DOI : 10.1016/j.cmet.2010.07.008

A. Monaco, C. Bertelson, S. Liechti-gallati, . Moser, and L. Kunkel, An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus, Genomics, vol.2, issue.1, pp.90-95, 1988.
DOI : 10.1016/0888-7543(88)90113-9

S. England, . Nicholson, . Lv, M. Johnson, . Forrest et al., Very mild muscular dystrophy associated with the deletion of 46% of dystrophin, Nature, vol.343, issue.6254, pp.180-182, 1990.
DOI : 10.1038/343180a0

D. Love, . Flint, . Tj, S. Genet, . Middleton-price et al., Becker muscular dystrophy patient with a large intragenic dystrophin deletion: implications for functional minigenes and gene therapy., Journal of Medical Genetics, vol.28, issue.12, pp.860-864, 1991.
DOI : 10.1136/jmg.28.12.860

K. Anthony, S. Cirak, S. Torelli, G. Tasca, L. Feng et al., Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials, Brain, vol.134, issue.12, pp.3547-3559, 2011.
DOI : 10.1093/brain/awr291

S. Errington, C. Mann, . Fletcher, . Wilton, and . Sd, Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene, The Journal of Gene Medicine, vol.9, issue.6, pp.518-527, 2003.
DOI : 10.1002/jgm.361

A. Aartsma-rus, . Janson, . Aa, J. Heemskerk, D. Winter et al., Therapeutic Modulation of DMD Splicing by Blocking Exonic Splicing Enhancer Sites with Antisense Oligonucleotides, Annals of the New York Academy of Sciences, vol.108, issue.1, pp.74-76, 2006.
DOI : 10.1089/oli.2005.15.284

A. Manzur and F. Muntoni, Diagnosis and new treatments in muscular dystrophies, Journal of Neurology, Neurosurgery & Psychiatry, vol.80, issue.7, pp.622-630, 2009.
DOI : 10.1136/jnnp.2008.158329
URL : https://hal.archives-ouvertes.fr/hal-00552718

A. Aartsma-rus, . Van-ommen, and . Gj, Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications, RNA, vol.13, issue.10, pp.1609-1624, 2007.
DOI : 10.1261/rna.653607

J. Van-deutekom, . Janson, . Aa, . Ginjaar, . Ib et al., Local Dystrophin Restoration with Antisense Oligonucleotide PRO051, New England Journal of Medicine, vol.357, issue.26, pp.2677-2686, 2007.
DOI : 10.1056/NEJMoa073108

M. Kinali, V. Arechavala-gomeza, L. Feng, S. Cirak, D. Hunt et al., Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study, The Lancet Neurology, vol.8, issue.10, pp.918-928, 2009.
DOI : 10.1016/S1474-4422(09)70211-X

S. Cirak, V. Arechavala-gomeza, M. Guglieri, L. Feng, S. Torelli et al., Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study, The Lancet, vol.378, issue.9791, pp.595-605, 2011.
DOI : 10.1016/S0140-6736(11)60756-3

N. Goemans, M. Tulinius, . Van-den-akker, . Jt, . Burm et al., Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy, New England Journal of Medicine, vol.364, issue.16, pp.1513-1522, 2011.
DOI : 10.1056/NEJMoa1011367

D. Angelis, . Fg, O. Sthandier, B. Berarducci, S. Toso et al., Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in ??48-50 DMD cells, Proceedings of the National Academy of Sciences, vol.99, issue.14, pp.9456-9461, 2002.
DOI : 10.1073/pnas.142302299

C. Brun, D. Suter, C. Pauli, P. Dunant, H. Lochmüller et al., U7 snRNAs induce correction of mutated dystrophin pre-mRNA by exon skipping, Cellular and Molecular Life Sciences (CMLS), vol.60, issue.3, pp.557-566, 2003.
DOI : 10.1007/s000180300047

R. Benchaouir, M. Meregalli, A. Farini, G. Antona, M. Belicchi et al., Restoration of Human Dystrophin Following Transplantation of Exon-Skipping-Engineered DMD Patient Stem Cells into Dystrophic Mice, Cell Stem Cell, vol.1, issue.6, pp.646-657, 2007.
DOI : 10.1016/j.stem.2007.09.016

A. Goyenvalle, A. Vulin, F. Fougerousse, F. Leturcq, J. Kaplan et al., Rescue of Dystrophic Muscle Through U7 snRNA-Mediated Exon Skipping, Science, vol.306, issue.5702, pp.1796-1799, 2004.
DOI : 10.1126/science.1104297

M. Denti, A. Rosa, G. Antona, O. Sthandier, D. Angelis et al., Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model, Proceedings of the National Academy of Sciences, vol.103, issue.10, pp.3758-3763, 2006.
DOI : 10.1073/pnas.0508917103

M. Denti, A. Rosa, G. Antona, O. Sthandier, D. Angelis et al., Chimeric Adeno-Associated Virus/Antisense U1 Small Nuclear RNA Effectively Rescues Dystrophin Synthesis and Muscle Function by Local Treatment of mdx Mice, Human Gene Therapy, vol.0, issue.0, pp.565-574, 2006.
DOI : 10.1089/hum.2006.17.ft-200

A. Goyenvalle, A. Babbs, J. Wright, V. Wilkins, D. Powell et al., Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping, Human Molecular Genetics, vol.21, issue.11, pp.2559-2571, 2012.
DOI : 10.1093/hmg/dds082

D. Cacchiarelli, I. Legnini, J. Martone, V. Cazzella, D. Amico et al., miRNAs as serum biomarkers for Duchenne muscular dystrophy, EMBO Molecular Medicine, vol.102, issue.5, pp.258-265, 2011.
DOI : 10.1002/emmm.201100133
URL : https://hal.archives-ouvertes.fr/pasteur-00976762

S. Tuffery-giraud, C. Béroud, F. Leturcq, R. Yaou, D. Hamroun et al., Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase, Human Mutation, vol.23, issue.6, pp.934-945, 2009.
DOI : 10.1002/humu.20976

A. Aartsma-rus, I. Fokkema, J. Verschuuren, I. Ginjaar, J. Van-deutekom et al., Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations, Human Mutation, vol.7, issue.3, pp.293-299, 2009.
DOI : 10.1002/humu.20918

Y. Zhuang, . Weiner, and . Am, A compensatory base change in U1 snRNA suppresses a 5??? splice site mutation, Cell, vol.46, issue.6, pp.827-835, 1986.
DOI : 10.1016/0092-8674(86)90064-4

L. Cartegni, J. Wang, Z. Zhu, . Zhang, . Krainer et al., ESEfinder: a web resource to identify exonic splicing enhancers, Nucleic Acids Research, vol.31, issue.13, pp.3568-3571, 2003.
DOI : 10.1093/nar/gkg616

A. Aartsma-rus, D. Winter, . Cl, . Janson, . Aa et al., Functional Analysis of 114 Exon-Internal AONs for Targeted DMD Exon Skipping: Indication for Steric Hindrance of SR Protein Binding Sites, Oligonucleotides, vol.15, issue.4, pp.284-297, 2005.
DOI : 10.1089/oli.2005.15.284

D. Bonci, A. Cittadini, . Latronico, . Mv, U. Borello et al., ???Advanced??? generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo, Gene Therapy, vol.10, issue.8, pp.630-636, 2003.
DOI : 10.1038/sj.gt.3301936

S. Buonomo, A. Michienzi, D. Angelis, . Fg, and I. Bozzoni, The Rev protein is able to transport to the cytoplasm small nucleolar RNAs containing a Rev binding element, RNA, vol.5, issue.8, pp.993-1002, 1999.
DOI : 10.1017/S1355838299990064

C. Delaporte, . Dehaupas, and M. Fardeau, Comparison between the growth pattern of cell cultures from normal and Duchenne dystrophy muscle, Journal of the Neurological Sciences, vol.64, issue.2, pp.149-160, 1984.
DOI : 10.1016/0022-510X(84)90033-9

F. Piétri-rouxel, C. Gentil, S. Vassilopoulos, D. Baas, E. Mouisel et al., DHPR ??1S subunit controls skeletal muscle mass and morphogenesis, The EMBO Journal, vol.4, issue.3, pp.643-654, 2010.
DOI : 10.1016/j.cmet.2007.11.004

M. Cesana, D. Cacchiarelli, I. Legnini, T. Santini, O. Sthandier et al., A Long Noncoding RNA Controls Muscle Differentiation by Functioning as a Competing Endogenous RNA, Cell, vol.147, issue.2, pp.358-369, 2011.
DOI : 10.1016/j.cell.2011.09.028

O. Scott, . Hyde, . Sa, . Goddard, and V. Dubowitz, Quantitation of muscle function in children: A prospective study in duchenne muscular dystrophy, Muscle & Nerve, vol.197, issue.4, pp.291-301, 1982.
DOI : 10.1002/mus.880050405

S. Harper, M. Hauser, C. Dellorusso, D. Duan, R. Crawford et al., Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy, Nature Medicine, vol.8, issue.3, pp.253-261, 2002.
DOI : 10.1038/nm0302-253

S. Cirak, L. Feng, K. Anthony, V. Arechavala-gomeza, S. Torelli et al., Restoration of the Dystrophin-associated Glycoprotein Complex After Exon Skipping Therapy in Duchenne Muscular Dystrophy, Molecular Therapy, vol.20, issue.2, pp.462-467, 2012.
DOI : 10.1038/mt.2011.248